KEYNOTE-689: A step forward or a leap of faith in resectable LA-HNSCC?
- PMID: 40997590
- DOI: 10.1016/j.oraloncology.2025.107724
KEYNOTE-689: A step forward or a leap of faith in resectable LA-HNSCC?
Keywords: Cisplatin; Head neck cancer; Immunotherapy; Locally advanced disease; Pembrolizumab; Radiotherapy; Surgery.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
LinkOut - more resources
Full Text Sources
